Reacción a "Both the drug orforglipron and a probiotic supplement help patients with obesity maintain their weight loss, according to two independent clinical trials "

This study is very important because it focuses not so much on losing weight, but on maintaining the benefits, something we are currently concerned about. Previous studies showed that stopping the medication could lead to a rebound effect if things weren’t done properly. That is why we are so committed to incorporating certain key concepts into obesity therapy that allow us to understand and treat it effectively, such as the fact that, as a chronic and complex condition, it requires long-term treatment and sustained support over time. That is why the maintenance phase is so important.

In this trial on orforglipron — I prefer not to comment on the other one as I am not as familiar with it — it is demonstrated and published how strategies based on oral obesity therapy using a small molecule that acts on GLP-1 receptors maintain that benefit over time (52 weeks). It is true that longer studies are needed, but these will surely be reported in due course. This is very good news because what we want is to maintain that benefit. We currently have clinical trials underway with different alternatives for that maintenance phase.